| Literature DB >> 21511051 |
Jagat R Kanwar1, Sishir K Kamalapuram, Rupinder K Kanwar.
Abstract
Survivin, a prominent anticancer target, is ubiquitously expressed in a plethora of cancers and the evolving complexity in functional regulation of survivin is yet to be deciphered. However, pertaining to the recent studies, therapeutic modulation of survivin is critically regulated by interaction with prominent cell-signalling pathways [HIF-1α, HSP90, PI3K/AKT, mTOR, ERK, tumour suppressor genes (p53, PTEN), oncogenes (Bcl-2, Ras)] and a wide range of growth factors (EGFR, VEGF, among others). In our article we discuss, in detail, an overview of the recent developments in the pharmacological modulation of survivin via cell-signalling paradigms and antisurvivin therapeutics, along with an outlook on therapeutic management of survivin in drug-resistant cancers.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21511051 DOI： 10.1016/j.drudis.2011.04.001
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851